[en] OBJECTIVES: Scheduled maintenance therapy with infliximab decreases the risk of infusion reactions. Many centers have accelerated infusion times to 1 h in selected patients who tolerate 5 mg/kg infliximab infusions. The aim of this study was to compare the tolerability of 1-h and 2-h infliximab infusions in patients with inflammatory bowel disease (IBD) in a large single-center cohort. The primary end point was the incidence of infusion reactions in both groups. METHODS: A retrospective chart analysis of all IBD patients treated with infliximab was performed. Infusions in scheduled maintenance for at least 6 months from December 1994 until March 2009 were included. All patients were treated at the infusion unit or during hospitalization under standard operating procedures. Infusion parameters were prospectively recorded. From 2004, in patients tolerating at least four 2-h infusions, infusions were given over 1 h. RESULTS: As of March 2009, 953 patients with IBD (77.6% Crohn's disease, 22.4% ulcerative colitis) had been treated with infliximab. A total of 474 patients met the criteria of scheduled maintenance therapy. In total, 9,155 maintenance infusions were administered (4,307 over 1 h). No severe infusion reactions were documented. Mild acute reactions occurred in 0.6% (27/4,307) of the 1-h-infusion group and in 1.7% (80/4848) of the 2-h infusion group (P=0.0034). Delayed infusion reactions occurred in 0.2% of 1-h and 0.5% of 2-h infusion group patients (P=0.277). Loss of tolerability due to infusion reactions (1-h group 2.9% versus 2-h group 4.1%) was evenly distributed (P=0.34). None of the prespecified variables were predictive of infusion reactions in a multivariate analysis. CONCLUSIONS: In patients with IBD tolerating 2-h infusions of infliximab scheduled maintenance therapy, the infusion time can be shortened to 1 h with good tolerability. No severe reactions were observed and no predictors of infusion reactions were identified.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Breynaert, Christine
Ferrante, Marc
Fidder, Herma
Van Steen, Kristel ; Université de Liège - ULiège > Dép. d'électric., électron. et informat. (Inst.Montefiore) > Bioinformatique
Noman, Maja
Ballet, Vera
Vermeire, Severine
Rutgeerts, Paul
Van Assche, Gert
Language :
English
Title :
Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study.
Publication date :
2011
Journal title :
American Journal of Gastroenterology
ISSN :
0002-9270
eISSN :
1572-0241
Publisher :
Elsevier Science, New York, United States - New York
Hanauer SB, Feagan BG, Lichtenstein GR et al Maintenance Infiximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
Sands BE, Blank MA, PatelK et al Long-term treatment ofrectovaginal f stulas in Crohn's disease: response to Infiximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004; 2: 912-20. (Pubitemid 39335798)
Rutgeerts P, Sandborn WJ, Feagan BG et al Infiximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
Cheifetz A, Smedley M, Martin S et al Te incidence and management of infusion reactions to Infiximab: a large center experience. Am J Gastroenterol 2003;98:1315-24. (Pubitemid 36741529)
Ferrante M, Vermeire S, Fidder H et al Long-term outcome af er Infiximab for refractory ulcerative colitis. J Crohn's Colitis 2008; 2: 219-25.
Fidder H, Schnitzler F, Ferrante M et al Long-term safety of Infiximab for the treatment of Infammatory bowel disease: a single-centre cohort study Gut 2009;58:501-8.
Lees CW, Ali AI, Tompson AI et al Te safety profile of anti-tumour necrosis factor therapy in Infammatory bowel disease in clinical prac-tice: analysis of 620 patient-years follow-up. Aliment Pharmacol Ter 2009;29:286-97.
Schnitzler F, Fidder H, Ferrante M et al Long-term outcome of treatment with Infiximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
Ducharme J, Pelletier C, Zacharias R. Te safety of Infiximab infusions in the community setting. Can J Gastroenterol 2010; 24: 307-11.
Zabana Y, Domenech E, Manosa M et al Infiximab safety profile and long-term applicability in Infammatory bowel disease: 9-year experience in clinical practice. Aliment Pharmacol Ter 2010;31:553-60.
Buch MH, Bryer D, Lindsay S et al Shortening infusion times for inf ixi-mab administration. Rheumatology (Oxford) 2006;45:485-6.
Salzberg BA KK. Succesful one hour infusions of Infiximab for Crohn's dis-ease patients in an outpatient ofce setting. Presented at Digestive Disease Week 2004.
Befrits R Malmström L, ForsellA et al. One hour Infiximab infusions can replace two hour infusion in maintenance treatment of Crohn's disease without shortcomings, in patients treated for up to three years. Gastroen-terology 2008;134:A402.
Van Assche G, Vermeire S, Noman M et al Tolerability and safety of ac-celerated Infiximab infusions: a prospective referral central registry and patient survey J Crohn's Colitis 2010;4:429-333.
Clare DF, Alexander FC, Mike S et al Accelerated Infiximab infusions are safe and well tolerated in patients with Infammatory bowel disease. Eur J Gastroenterol Hepatol 2009;21:71-5.
Remicade SPC http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ human/medicines/000240/human-med-001023.jsp&murl=menus/medicines/medicines. jsp&mid=WC0b01ac058001d124 (last updated 27 April 2010).
Baert F, Noman M, Vermeire S et al Inffuence of immunogenicity on the long-term Effcacy of Infiximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
Moss AC, Fernandez-Becker N, Jo Kim K et al Te impact of Infiximab infusion reactions on long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ter 2008;28:221-7. (Pubitemid 351861971)
Colombel JF, Sandborn WJ, Reinisch W et al Infiximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;362: 1383-95.
Van Assche G, Magdelaine-Beuzelin C, D'Haens G et al Withdrawal of immunosuppression in Crohn's disease treated with scheduled Infiximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8. (Pubitemid 351790744)
